Daewoong and Recipharm extend API deal; U.K.'s national bio lab equipped for continuous manufacturing;

> Private equity is making money buying and selling contract manufacturers, a new report shows. Report

> Korea-based Daewoong has extended for 10 years a contract in which it will buy a minimum of €25 million worth of the API for its respiratory drug Erdosteine from Swedish CDMO Recipharm. Release

> The U.K.'s Centre for Process Innovation (CPI) says it and French CDMO Novasep have equipped the U.K.'s National Biologics Manufacturing Centre with Novasep's BioSC Lab to be used for continuous manufacturing. Release

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)